- Home
- LLY vs NVS Comparison
LLY vs NVS Comparison
Compare LLY & NVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LLY | NVS |
|---|---|---|
| Founded | 1876 | 1895 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 979.6B | 293.9B |
| IPO Year | 2007 | 2001 |
Fundamental Metrics
Financial Performance| Metric | LLY | NVS |
|---|---|---|
| Price | $1,281.49 | $160.31 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 19 | 5 |
| Target Price | ★ $1,218.84 | $144.00 |
| AVG Volume (30 Days) | ★ 2.0M | 1.6M |
| Earning Date | 04-30-2026 | 04-28-2026 |
| Dividend Yield | 0.81% | ★ 2.16% |
| EPS Growth | ★ 95.99 | N/A |
| EPS | ★ 16.19 | N/A |
| Revenue | ★ $65,179,000,000.00 | N/A |
| Revenue This Year | $27.15 | $2.30 |
| Revenue Next Year | $16.04 | $5.27 |
| P/E Ratio | $75.77 | ★ $23.13 |
| Revenue Growth | ★ 44.70 | N/A |
| 52 Week Low | $694.23 | $121.57 |
| 52 Week High | $1,249.45 | $170.46 |
Technical Indicators
Market Signals| Indicator | LLY | NVS |
|---|---|---|
| Relative Strength Index (RSI) | 64.37 | 61.02 |
| Support Level | $978.43 | $149.41 |
| Resistance Level | N/A | $160.46 |
| Average True Range (ATR) | 41.35 | 2.12 |
| MACD | 5.67 | 0.09 |
| Stochastic Oscillator | 89.71 | 99.17 |
Price Performance
Historical ComparisonAbout LLY Eli Lilly and Company
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio and Jaypirca for cancer; Mounjaro, Zepbound, Foundayo, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
About NVS Novartis AG
Novartis develops and manufactures innovative drugs. Key areas of drug development are oncology, immunology, neuroscience, respiratory, and cardiovascular, renal, and metabolic. It also has an established medicines business, which includes off-patent franchises. The company sells its products globally, with the United States constituting close to one-third of total revenue.